Ocular Therapeutix, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total net product revenue to be in the range of $55 million to $60 million, representing growth of between 26% to 38% over 2021. The growth is anticipated to be primarily driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.795 USD | -0.09% | -6.08% | +29.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.93% | 898M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022